A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2017

At a glance

  • Drugs AMG 176 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 12 Jun 2017 Planned End Date changed from 1 Jul 2020 to 30 Apr 2019.
    • 24 Jan 2017 Planned primary completion date changed from 1 Jul 2020 to 1 Apr 2019.
    • 30 Jun 2016 Planned End Date changed from 1 Mar 2019 to 1 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top